STAT3 and non-small cell lung carcinoma: Persistent STAT3 activation, driven by cytokines, growth factors, and mutations in EGFR and SRC kinases, has been observed in over 50% of NSCLC patients and is associated with chemoresistance, radioresistance, and immune evasion [55].